$DNLI Cashflow Statement | Understand Stock

$DNLI

$18.66 +$0.25 (1.36%) Close

$DNLI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Net accretion of discounts on marketable securities
Non-cash adjustment to operating lease expense
Right-of-use asset amortization for finance lease
Non-cash gain from divestiture of small molecule programs
Other non-cash items
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accruals and other current liabilities
Contract liabilities
Related party contract liability
Deferred research and development funding liability
Other non-current liabilities
Net cash used in operating activities
Investing activities
Maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of common stock in connection with Collaboration Agreements
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480
Proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of
Initial Closing
Public Offering
Total proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of
Proceeds from exercise of awards under equity incentive plans
Payments for finance lease right-of-use asset
Issuance costs related to the royalty financing
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosures of cash flow information
Tenant improvements provided by the landlord
Equity consideration received in the divestiture of small molecule programs (Note 13)
Increase in right-of-use asset due to lessor assets
Right-of-use asset obtained in exchange for new finance lease liabilities
Property and equipment purchases accrued but not yet paid
Cash paid for finance lease interest
Issuance costs incurred but not yet paid
Cash paid during the year for income taxes

Comments